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intervention measures for LDL, HDL, triglycerides, total choles-
terol, adherence and quality-of-life. A random-effects meta-
analysis combined data between pharmacist-intervention and
standard-care groups. Chi-square tested heterogeneity of effects.
Publication bias was assessed using funnel plots and Begg-
Mazumdar statistic. RESULTS: Fifty-one studies were found; 22
met inclusion/exclusion criteria. Study settings included medical
clinic/center (n = 11), community pharmacy (n = 8), hospital
(n = 2) and patient homes (n = 1). Patient education (77%) and
medication management (73%) were most common interven-
tions. The average patient follow-up period was 9.8  6.4
months. Quality of pharmacist-intervention studies was consid-
ered “fair” (65%, SD = 6.6%). Total cholesterol was signiﬁ-
cantly reduced from baseline (34.3  10.3 mg/dL, p < 0.001)
and also signiﬁcantly above control groups (22.0  10.4 mg/dL,
p = 0.034). LDL was reduced signiﬁcantly from baseline
(38.6  12.4 mg/dL, p = 0.002); but not signiﬁcantly more than
controls (22.1  12.0 mg/dL, p = 0.065). A clinically relevant
but not statistically signiﬁcant reduction in triglycerides was
found. Patients’ adherence to pharmacotherapeutic regimens (3/9
studies reported signiﬁcant results after pharmacists’ interven-
tions) and quality of life (2/2 signiﬁcant) were considered
possibly not sensitive and possibly sensitive to pharmacist
interventions, respectively. CONCLUSION: Total cholesterol
is sensitive to pharmacist’s interventions while LDL and
triglycerides levels are possibly sensitive to those interventions.
Further research should evaluate speciﬁc determinants of
pharmacist-sensitive outcomes.
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OBJECTIVE: New members of the TNF-signaling superfamily,
osteoprotegerin (OPG) and receptor activator of nuclear
factor-kB ligand (RANKL), are thought to play an important role
in vascular calciﬁcation and bone remodeling and might repre-
sent the molecular link between arterial calciﬁcation and bone
resorption. The purpose of this study was to determine whether
OPG and/or RANKL mediate the observed association between
coronary and bone calciﬁcation in postmenopausal women.
METHODS: Among the members of the Rancho Bernardo lon-
gitudinal study, 92 postmenopausal women (aged 58–81 years)
taking estrogen therapy (ET) who underwent assessment of bone
mineral density (BMD) and coronary artery calciﬁcation (CAC)
and had serum OPG and RANKL levels measured between
1998–2002 are the basis of this report. RESULTS: Neither OPG
nor RANKL levels varied among subjects with and without CAC
in multivariate analysis. Increase in BMD at the hip was associ-
ated with decrease in CAC (OR = 0.52; 95% CI: 0.29–0.93)
independent of age, fat-free mass, HDL cholesterol, current
smoking, and use of cholesterol-lowering medications. Other
skeletal sites demonstrated a similar pattern. Addition of
RANKL and/or OPG in the model had minimal effect on the
magnitude or statistical signiﬁcance of the BMD-CAC associa-
tion. Additionally, a test of interaction indicated that RANKL
and OPG are not signiﬁcant effect modiﬁers of the association.
CONCLUSION: Serum OPG and RANKL do not account for
the observed association between bone and coronary artery
calciﬁcation among postmenopausal women using ET.
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OBJECTIVE: Beta-blocker therapy, well established in the treat-
ment of CHF, is considered contraindicated in patients with
concomitant diabetes by many physicians due to concerns of
increased incidence of hypoglycemia, worsening dyslipidemia,
and decreased insulin sensitivity. Purpose of this study is to
determine the association between beta-blocker therapy and
hospitalization in patients with chronic heart failure (CHF) and
diabetes. METHODS: The study was a retrospective analysis
utilizing the pharmacy, inpatient and outpatient claims linked
with eligibility ﬁles for persons enrolled in the Georgia Medicaid
beneﬁts through the year 2001. Patients who received both diag-
nosis of chronic heart failure and diabetes were identiﬁed. The
study cohort was further categorized into treatment and com-
parison groups according to their exposure to Beta-blocker. A
stepwise logistic regression analysis was employed to assess the
association between taking beta-blocker and hospitalization
among CHF patients with diabetes. RESULTS: Three hundred
ninety patients with beta-blocker exposure and 642 not-exposed
patients were identiﬁed. Two hundred thirty eight patients were
hospitalized and 799 had no hospitalization. Majority of the
cohort was female 788 (76.36%), black 531 (51.45%) and in the
age group of 40–65 years 966 (93.60%). Metoprolol was the
most commonly used beta-blocker with 12,149 claims (51.83%)
followed by Carvedilol 6169 (26.32%). The most common
co-morbid conditions among patients were found to be Hyper-
tension, Ischemic Heart Disease and Chronic Obstructive Pulmo-
nary Disease. Diuretics, ACE inhibitors and Digoxin use were
found to be the common concurrent therapy taken by the
patients. After controlling for factors like age, race, gender,
common co-medications and co-morbid conditions, there was no
signiﬁcant association between hospitalization and beta-blockers
use in patients with Chronic Heart Failure and Diabetes.
CONCLUSION: Despite the potential contraindication, the
utilization of beta-blocker does not lead to a higher rate of
hospitalization among CHF patients with diabetes.
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OBJECTIVE: The Blood Pressure Success Zone (BPSZ) Program
is a nationwide initiative which provides blood pressure manage-
ment education to hypertensive patients and a complimentary
trial of antihypertensive medications. The BPSZ-BLISS (Longitu-
dinal Observational Study of Success) is an observational study
to evaluate BPSZ program effectiveness on blood pressure (BP)
control, compliance, persistence and treatment satisfaction.
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